Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for six to eight weeks, there is a critical need for new remedies, according to a recent...
Anurag Singh, PhD, assistant professor in the Department of Pharmacology and Experimental Therapeutics at Boston University School of Medicine presented his recent work on targeted therapeutics for colon cancer at the American Association of Cancer Research Annual Meeting in Chicago, IL. Singh's...
Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to...
Vicus Therapeutics, LLC, announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma)...
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, announced today that it has completed the spin-out of Onset Therapeutics, LLC, its wholly owned subsidiary focused on the Dermatology market. Onset will become part of PreCision Dermatology, Inc., a newly founded company that...
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that it has submitted a formal appeal to the Office of New Drugs in the U.S. Food and Drug Administration's Center for Drug Evaluation and Research regarding the agency's decision from earlier this year on the pixantrone New Drug...
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that CTI's Marketing Authorization Application ("MAA") seeking approval for Pixuvri™ (pixantrone dimaleate) for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") was...
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that The NASDAQ Stock Market ("NASDAQ") has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was...
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from a clinical evaluation of its lead program in gout, NU1618, and pre-clinical data describing the mechanism of action for the tranilast component of NU1618, have been accepted for...
Alulim Pharma, Inc., an aerosol therapeutics company, emerged with a seasoned team and a robust portfolio of pre-clinical and clinical data, along with existing intellectual property protection. Alulim's proven platform technology allows drugs, both water-soluble and insoluble, to be uniquely...
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies (the "Company"), has announced that it has contracted with the clinical research organization (CRO) Averion International Corp. to conduct its planned Phase...
Guided Therapeutics, Inc. (GT) (OTCBB: GTHP) announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009. The three-year grant provides additional resources to commercialize and bring to market the...
The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These...
Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a leading supplier of manufacturing solutions to the life sciences industries, announce...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced the National Heart, Lung, and Blood Institute (NHLBI) has awarded a $1 million Cardiac Translational Research Implementation Program (C-TRIP) grant to support research on Glial Growth Factor 2 (GGF2), a novel investigational agent for the...
Edge Therapeutics, Inc. announced that it has received $100,000 in financing from the New Jersey Economic Development Authority (NJEDA) to supplement an Edison Innovation R&D Grant of $500,000 awarded to Edge in November 2009. Edge will use the funding for further development of its novel...
Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced today that a phase 2a study of NU1618, the company's lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia. "This successful...
IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, announced that it has raised $8 million through a note offering to existing shareholders. The new funding will be used to further develop its pipeline of cancer vaccine candidates, including its lead...
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) (the "Company") announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but...
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201...